CK Life Sciences Int'l., (Holdings) Inc. Share Price

Equities

775

KYG2176J1058

Food Processing

Market Closed - Hong Kong S.E. 01:38:20 26/04/2024 pm IST 5-day change 1st Jan Change
0.345 HKD +1.47% Intraday chart for CK Life Sciences Int'l., (Holdings) Inc. +2.99% -44.35%

Financials

Sales 2022 5.28B 674M 56.19B Sales 2023 5.32B 680M 56.69B Capitalization 5.96B 761M 63.47B
Net income 2022 132M 16.86M 1.41B Net income 2023 17M 2.17M 181M EV / Sales 2022 2.43 x
Net Debt 2022 5.24B 670M 55.83B Net Debt 2023 5.25B 671M 55.97B EV / Sales 2023 2.11 x
P/E ratio 2022
57.5 x
P/E ratio 2023
346 x
Employees 1,932
Yield 2022
1.01%
Yield 2023
-
Free-Float 25.02%
More Fundamentals * Assessed data
Dynamic Chart
CK Life Sciences to Present Pre-Clinical Data for Two Cancer Vaccines; Shares Up 11% MT
CK Life Sciences Int'l., Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
XtalPi and CK Life Sciences Ink Agreement to Develop Cancer Molecular Diagnostic Models Using AI and Biomarker Data CI
CK Life Sciences to Present Preclinical Study of Cancer Vaccines at US Immunotherapy Conference MT
Ck Life Sciences Int'l., Inc. Announces Preclinical Data for Its Investigational Dual-Antigen Cancer Vaccines, Co-Targeting Prame and PD-L1 CI
CK Life Sciences International's Profit Slumps 43% in H1; Shares Down 3% MT
CK Life Sciences Int'l., Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
CK Life Sciences Int'l., Inc. Announces Ordinary Final Dividend for the Year Ended 31 December 2022, Payment Date 05 June 2023 CI
CK Life Sciences Int'l., Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
XtalPi Inc. and CK Life Sciences to Collaborate in Ai-Empowered Tumour Vaccine Research and Development, Opening A New Paradigm for Scientific Innovation CI
CK Life Sciences Int'l., Inc. Announces Retirement of Independent Non-Executive Director and Change in Composition of the Remuneration Committee CI
CK Life Sciences' H1 Profit Down 35% MT
CK Life Sciences Int'l., Inc. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
CK Life Sciences Investors Acquire Stake in Pharus for $5.5 Million Each MT
CK Life Sciences Int'l., Inc. Announces Ordinary Final Cash Dividend for the Year Ended 31 December 2021, Payable on 01 June 2022 CI
More news
1 day+1.47%
1 week+2.99%
Current month+2.99%
1 month-4.17%
3 months-40.52%
6 months-48.51%
Current year-44.35%
More quotes
1 week
0.33
Extreme 0.33
0.37
1 month
0.30
Extreme 0.3
0.42
Current year
0.30
Extreme 0.3
0.62
1 year
0.30
Extreme 0.3
0.82
3 years
0.30
Extreme 0.3
1.28
5 years
0.30
Extreme 0.3
1.34
10 years
0.30
Extreme 0.3
1.34
More quotes
Managers TitleAgeSince
Chief Executive Officer 69 01/02/01
Director of Finance/CFO 64 01/05/01
President 77 01/02/01
Members of the board TitleAgeSince
Director/Board Member 82 01/02/01
Chairman 59 01/02/01
President 77 01/02/01
More insiders
Date Price Change Volume
26/24/26 0.345 +1.47% 6,108,600
25/24/25 0.34 -1.45% 8,846,142
24/24/24 0.345 +2.99% 2,165,080
23/24/23 0.335 -1.47% 1,856,000
22/24/22 0.34 +1.49% 1,623,128

Delayed Quote Hong Kong S.E., April 26, 2024 at 01:38 pm IST

More quotes
CK Life Sciences Intl (Holdings) Inc is an investment holding company principally engaged in the development and sales of healthcare products. The Company operates through two segments. The Health segment is engaged in the development, production, marketing and sales of healthcare and pharmaceutical products. The healthcare brands under the Company include Lipa, Vitaquest and Sante Naturelle, among others. Its pharmaceutical products include cancer-related pharmaceuticals and painkillers, among others. The Agriculture-related Businesses segment is engaged in the operation of vineyards, as well as the development, production, marketing and sales of agriculture and related products. Its agricultural products include fertilizers and crop protection products, among others.
More about the company